The goal of this core is to provide investigators in the SPORE high quality patient data, DNA, RNA, serum, and pancreas tissues from consented pancreatic cancer patients and to make these resources available for future studies. The activities of the CORE will be conducted in a way that does not compromise patient confidentiality, yet will be as comprehensive as possible (within its scope) in the materials that are provided. The acquisition of human tissue and subsequent cellular/molecular analysis of that tissue within the context of patient data are key to many laboratory-based studies of cancer. The Mayo Clinic has a strong tradition of tissue acquisition and patient data records. Paraffin embedded tissues, histological slides, and associated patient charts from surgeries performed since the first decade of the 1900's are maintained in Mayo's Tissue Registry and the Mayo Archives. Today, the Tissue Acquisition and Cellular/Molecular Analysis (TACMA) Shared Resource of the Mayo Clinic Cancer Center provides normal and neoplastic human tissues for cancer research at Mayo, and is a resource of expertise, collaborative support, and service for pathology, immunohistochemistry, in situ hybridization, laser capture microdissection, tissue microarray preparation, and RT-PCR. The Patient Registry and Biospecimens Core of this SPORE will be integrated with the existing TACMA Shared Resource in order to provide a coordinated, centralized, dedicated program for procuring, processing, and assessing biospecimens and patient data from pancreatic cancer patients. To achieve our goals, we have assembled a clinical research team of experts in pancreatic cancer, consisting of Drs. S. Chari (gastroenterologist), M. Farnell (GI surgeon), R. Goldberg (medical oncologist), G. Kim (oncologist, Jacksonville), G. Petersen (epidemiologist), L. Miller (GI research, Scottsdale), and M. Sarr (GI surgeon), to support the activities of the Patient Registry and Biospecimens Core under the combined leadership of Dr. W. Lingle, Co-Director of the TACMA Shared Resource of the Mayo Clinic Cancer Center, and Dr. T. Smyrk, anatomic pathologist. The Patient Registry and Biospecimens Core activities will be closely coordinated with the Animal Models and Xenograft Core, to deliver tissue of highest quality for xenograft culture, and with the Biostatistics Core, for data management and analyses. We will install new infrastructures at Mayo Clinic Scottsdale and Mayo Clinic Jacksonville to recruit pancreatic cancer patients and their biospecimens into a unified registry under this Core.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory Grants (P20)
Project #
1P20CA102701-01
Application #
6824787
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2003-09-29
Project End
2008-08-31
Budget Start
Budget End
Support Year
1
Fiscal Year
2003
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
McWilliams, Robert R; Wieben, Eric D; Chaffee, Kari G et al. (2018) CDKN2A Germline Rare Coding Variants and Risk of Pancreatic Cancer in Minority Populations. Cancer Epidemiol Biomarkers Prev 27:1364-1370
Kanamori, Karina S; de Oliveira, Guilherme C; Auxiliadora-Martins, Maria et al. (2018) Two Different Methods of Quantification of Oxidized Nicotinamide Adenine Dinucleotide (NAD+) and Reduced Nicotinamide Adenine Dinucleotide (NADH) Intracellular Levels: Enzymatic Coupled Cycling Assay and Ultra-performance Liquid Chromatography (UPLC)-Mass Bio Protoc 8:
Paradise, Brooke D; Barham, Whitney; Fernandez-Zapico, Martín E (2018) Targeting Epigenetic Aberrations in Pancreatic Cancer, a New Path to Improve Patient Outcomes? Cancers (Basel) 10:
Tarragó, Mariana G; Chini, Claudia C S; Kanamori, Karina S et al. (2018) A Potent and Specific CD38 Inhibitor Ameliorates Age-Related Metabolic Dysfunction by Reversing Tissue NAD+ Decline. Cell Metab 27:1081-1095.e10
Chini, Eduardo N; Chini, Claudia C S; Espindola Netto, Jair Machado et al. (2018) The Pharmacology of CD38/NADase: An Emerging Target in Cancer and Diseases of Aging. Trends Pharmacol Sci 39:424-436
Storz, Peter (2017) Acinar cell plasticity and development of pancreatic ductal adenocarcinoma. Nat Rev Gastroenterol Hepatol 14:296-304
Kim, Jungsun; Bamlet, William R; Oberg, Ann L et al. (2017) Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers. Sci Transl Med 9:
Espindola-Netto, Jair Machado; Chini, Claudia C S; Tarragó, Mariana et al. (2017) Preclinical efficacy of the novel competitive NAMPT inhibitor STF-118804 in pancreatic cancer. Oncotarget 8:85054-85067
Ding, Li; Liou, Geou-Yarh; Schmitt, Daniel M et al. (2017) Glycogen synthase kinase-3? ablation limits pancreatitis-induced acinar-to-ductal metaplasia. J Pathol 243:65-77
Cho, Dong Seong; Doles, Jason D (2017) Single cell transcriptome analysis of muscle satellite cells reveals widespread transcriptional heterogeneity. Gene 636:54-63

Showing the most recent 10 out of 52 publications